The global endoscopic retrograde cholangiopancreatography market size reached USD 1.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.8 Billion by 2033, exhibiting a growth rate (CAGR) of 5.58% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 1.7 Billion |
Market Forecast in 2033
|
USD 2.8 Billion |
Market Growth Rate 2025-2033 | 5.58% |
Endoscopic retrograde cholangiopancreatography (ERCP) is an imaging technique that diagnoses and treats abnormalities in the liver, gallbladder, bile ducts, and pancreas. It combines X-rays and a long, flexible, lightweight endoscope tube that passes through the esophagus, mouth, and stomach. It helps detect blockages, stones, infections, and tumors in the bile duct and fluid leakage from the pancreatic duct. Besides this, it is a less invasive procedure than open surgery and provides more detailed and accurate information about the pancreaticobiliary system. As a result, the demand for endotherapy devices is increasing across the globe to investigate dysphagia, diarrhea, weight loss, heartburn, and stool blood.
The growing global population and the rising prevalence of various chronic gastrointestinal (GI) and incessant biliary medical disorders, including Barrett's disease, biliary, liver, Crohn's, inflammatory bowel, and peptic ulcer disease, and gastroesophageal reflux disorder (GERD), represent one of the key factors positively influencing the market. In addition, the increasing occurrence of benign pancreas and liver tumors, especially among the geriatric population, along with the growing occurrence of cancer across the globe, is driving the market. In line with this, the expansion of hospitals and diagnostic centers is increasing the need for imaging techniques propelling the market growth. Furthermore, rising investments by governments and healthcare organizations of various countries in advanced endoscopy devices and improve endoscopy research is strengthening the market growth. Apart from this, the shifting consumer preference toward minimally invasive surgeries for a speedy recovery and minimal pain and rising awareness about ERCP devices like sphincterotomes are offering a favorable market outlook. Moreover, continuous improvements in healthcare infrastructure and a considerable rise in medical tourism are expected to propel market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global endoscopic retrograde cholangiopancreatography market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product, procedure and end user.
Breakup by Product:
Breakup by Procedure:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Boston Scientific Corporation, CONMED Corporation, Cook Group Incorporated, Fujifilm Holdings Corporation, Hobbs Medical Inc., Johnson & Johnson, Medi-Globe GmbH, Medtronic plc, Olympus Corporation, Shaili Endoscopy, Steris Corporation and Telemed Systems Inc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Product, Procedure, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Boston Scientific Corporation, CONMED Corporation, Cook Group Incorporated, Fujifilm Holdings Corporation, Hobbs Medical Inc., Johnson & Johnson, Medi-Globe GmbH, Medtronic plc, Olympus Corporation, Shaili Endoscopy, Steris Corporation and Telemed Systems Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global endoscopic retrograde cholangiopancreatography market was valued at USD 1.7 Billion in 2024.
We expect the global endoscopic retrograde cholangiopancreatography market to exhibit a CAGR of 5.58% during 2025-2033.
The rising prevalence of various chronic Gastrointestinal (GI) and incessant biliary medical disorders, along with the increasing consumer preference towards minimally invasive surgeries for a speedy recovery and minimal pain, is primarily driving the global endoscopic retrograde cholangiopancreatography market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective dysphagia, diarrhea, and heartburn treatment procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for endoscopic retrograde cholangiopancreatography.
Based on the product, the global endoscopic retrograde cholangiopancreatography market can be segmented into endoscope, endotherapy devices, visualization systems, energy devices, and others. Currently, endotherapy devices hold the majority of the total market share.
Based on the procedure, the global endoscopic retrograde cholangiopancreatography market has been divided into biliary sphincterotomy, biliary stenting, biliary dilatation, pancreatic sphincterotomy, pancreatic duct stenting, and pancreatic duct dilatation. Among these, biliary sphincterotomy currently exhibits a clear dominance in the market.
Based on the end user, the global endoscopic retrograde cholangiopancreatography market can be categorized into hospitals and clinics, ambulatory surgery centers, and others. Currently, hospitals and clinics account for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global endoscopic retrograde cholangiopancreatography market include Boston Scientific Corporation, CONMED Corporation, Cook Group Incorporated, Fujifilm Holdings Corporation, Hobbs Medical Inc., Johnson & Johnson, Medi-Globe GmbH, Medtronic plc, Olympus Corporation, Shaili Endoscopy, Steris Corporation, and Telemed Systems Inc.